NCT Number: NCT02338583
Powered Surgical Stapler in VATS Lung Resection Procedures in China
This prospective, single-arm multi-center study will provide clinical data in an observational setting using the Echelon Flex™ 45 and 60 Powered ENDOPATH® Stapler Articulating Endoscopic Linear Cutters (study Endocutter). Individuals undergoing VATS lobectomy for suspected or confirmed Non Small Cell Lung Cancer (NSCLC), or individuals undergoing VATS diagnostic wedge resection in accordance with their institution's Standard of care (SOC), and who meet study entry criteria, may be enrolled.
Study procedures will include a wedge resection, wedge resection followed by lobectomy of the same lobe, or lobectomy.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Beijing Cancer Hospital, Beijing, China
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Suspected or confirmed of NSCLC (up to and including Stage II), or individuals undergoing VATS diagnostic wedge resection in accordance with their institution's Standard of care (SOC);
- Scheduled for lung resection surgery (lobectomy or wedge resection) involving only one lobe of the lung;
- Performance status 0-1 (Eastern Cooperative Oncology Group classification);
- ASA score < 3;
- No prior history of VATS or open lung surgery;
- Willing to give consent and comply with study-related evaluation and treatment schedule; and
- At least 18 years of age.
Exclusion criteria
Subjects satisfying the following criteria will be eligible for participation in this study:
- Suspected or confirmed of NSCLC (up to and including Stage II), or individuals undergoing VATS diagnostic wedge resection in accordance with their institution's Standard of care (SOC);
- Scheduled for lung resection surgery (lobectomy or wedge resection) involving only one lobe of the lung;
- Performance status 0-1 (Eastern Cooperative Oncology Group classification);
- ASA score < 3;
- No prior history of VATS or open lung surgery;
- Willing to give consent and comply with study-related evaluation and treatment schedule; and
- At least 18 years of age.
Treatment and study plan
Primary outcomes
-
Occurrence of prolonged air leaks
Time frame: 30 days
Secondary outcomes
-
2.Occurrence of postoperative air leaks
Time frame: 30 days
-
Length of stay (LOS)
Time frame: 30 days
-
Volume of estimated intra-operative blood loss
Time frame: Intra-operative
-
5.Time to chest tube removal
Time frame: 30 days
Sponsors and collaborators
Lead sponsor
Ethicon Endo-Surgery
Industry
Registry information
Official study title
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in China
Important dates
- Study start
- 2014
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Jan 14, 2015
- Registry last updated
- Aug 11, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
NCT06139419
Bronchial Neoplasms, Carcinoma, Bronchogenic
Guangzhou, Guangdong, China
View Trial DetailsStudy of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
NCT02718066
Adenocarcinoma, Bronchial Neoplasms
Phoenix, Arizona, United States
View Trial DetailsHybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer
NCT05348668
Bronchial Neoplasms, Carcinoma, Bronchogenic
Hefei, Anhui, China
View Trial DetailsEfficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer
NCT04702009
Advanced Lung Carcinoma, Bronchial Neoplasms
Shanghai, Shanghai Municipality, China
View Trial Details